AstraZeneca (AZN) Tops Q2 EPS by 93c, Beats on Revenue

AstraZeneca (NASDAQ: AZN) reported Q2 EPS of $1.72, $0.93 better than the analyst estimate of $0.79. Revenue for the quarter came in at $10.77 billion versus the consensus estimate of $10.51 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• C1 Fund reports portfolio growth and share repurchase activity